Internal Medicine, Medical Oncology · Houston, TX
NPI
1891947735
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
6400 Fannin St, 2900
Houston, TX, 77030
Phone (713) 704-3961
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
326 services
Medicare patients, 2024
99
Average age 74
Drug cost, 2024
$3.4M
1,031 prescriptions
Company payments, 2025
$147K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Putao Cen was code 99215 (office e&m - established), 181 times for 56 patients. In total Putao Cen billed 326 services in 10 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 181 | 56 | $109.23 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 59 | 27 | $13.15 | $776 |
| 99223 Hospital E&M - Initial | Facility | 22 | 22 | $138.24 | $3,041 |
| 99205 Office E&M - New | Office | 19 | 19 | $130.10 | $2,472 |
| 99233 Hospital E&M - Subsequent | Facility | 18 | 12 | $94.80 | $1,706 |
| 99214 Office E&M - Established | Office | 14 | 12 | $77.54 | $1,086 |
By year: 2022 $39K for 355 services; 2023 $25K for 227 services; 2024 $30K for 326 services.
Medicare prescription drug claims, 2024
In 2024, the drug Putao Cen prescribed most often to Medicare patients was Abiraterone Acetate, with 165 prescriptions and refills. In total Putao Cen wrote 1,031 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 165 | 165 | 26 | $170K |
| Ondansetron Hcl Generic | 98 | 98 | 52 | $2,367 |
| Prednisone Generic | 93 | 175 | 29 | $492 |
| Lenvima Lenvatinib Mesylate | 61 | 61 | 11 | $1.4M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 39 | 39 | 16 | $1,034 |
| Eliquis Apixaban | 35 | 47 | Under 11 | $27K |
| Lonsurf Trifluridine/Tipiracil Hcl | 35 | 40 | Under 11 | $403K |
| Zarxio Filgrastim-Sndz | 34 | 34 | Under 11 | $48K |
| Creon Lipase/Protease/Amylase | 31 | 48 | 14 | $83K |
| Zenpep Lipase/Protease/Amylase | 30 | 35 | Under 11 | $35K |
| Prochlorperazine Maleate Generic | 29 | 29 | 25 | $580 |
| Imatinib Mesylate Generic | 25 | 25 | Under 11 | $1,726 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 25 | 25 | 16 | $505 |
| Levothyroxine Sodium Generic | 22 | 50 | Under 11 | $249 |
| Gabapentin Generic | 21 | 39 | Under 11 | $341 |
Brand drugs: - claims; generic drugs: 717 claims; opioid claims: 70.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Putao Cen $147K ($147K in general payments such as food, travel and fees) from 13 companies. The largest payer was Astellas Pharma US Inc with $51K.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 30 | $51K |
| Taiho Oncology, Inc. 4578.T | 22 | $44K |
| Eisai Inc. 4523.T | 19 | $33K |
| Merck Sharp & Dohme LLC MRK | 8 | $13K |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $2,891 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $2,550 |
| Tempus AI, Inc TEM | 3 | $201 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $143 |
| Immunocore Limited IMCR | 1 | $121 |
| Pfizer Inc. PFE | 4 | $90.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.